TODAY试验干预后不同治疗组对血糖失败与β细胞功能的影响
TODAY试验显示,在青少年2型糖尿病中,二甲双胍联合罗格列酮组的血糖失败率显著低于二甲双胍单药组或二甲双胍联合强化生活方式干预组。研究结束时停用罗格列酮并恢复常规糖尿病管理,本研究对三个原治疗组追加随访36个月,报告干预后血糖失败率及胰岛素敏感性与β细胞功能结局。结果显示,TODAY2随访36个月期间血糖失败率按原治疗组划分无差异,胰岛素敏感性与β细胞功能均快速恶化且组间无差异。
要点
- 罗格列酮作为第二种药物降低血糖失败率的额外获益在停药后未能维持。
- TODAY2常规管理36个月内胰岛素敏感性与β细胞功能快速恶化。
- 需针对青少年2型糖尿病的快速进展采取更多措施以预防长期并发症。
核心结论
- 罗格列酮作为第二种药物预防青少年2型糖尿病血糖失败的额外获益在停药后未持续。
- TODAY2随访36个月期间血糖失败率按原治疗组划分无差异。
- 胰岛素敏感性与β细胞功能在TODAY2常规管理36个月内快速恶化且组间无差异。
研究设计与样本
- TODAY为随机对照试验,共699例参与者被随机分组。
- 572例TODAY参与者进入TODAY2观察性随访。
- TODAY2追加随访36个月,比较三个原治疗组的干预后结局。
- 进行口服葡萄糖耐量试验并计算胰岛素敏感性、胰岛素生成指数与口服处置指数。
主要发现
- TODAY2随访36个月期间,血糖失败率按原治疗组划分无差异。
- 胰岛素敏感性与β细胞功能在TODAY2的36个月常规糖尿病管理期间快速恶化。
- 胰岛素敏感性与β细胞功能的恶化按原治疗组划分无差异。
关键数值与推荐
- 血糖失败定义:6个月内HbA1c≥8%,或TODAY期间急性代谢失代偿后3个月内无法脱离临时胰岛素治疗,或TODAY2连续两次访视HbA1c持续≥8%。
临床怎么用
- 青少年2型糖尿病使用罗格列酮作为第二种药物带来的血糖失败预防获益在停药后不持续。
- 停药后仍需关注胰岛素敏感性与β细胞功能的快速恶化。
- 需加强干预以应对青少年2型糖尿病的快速进展并预防长期并发症。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The Treatment Options for type 2 Diabetes in Adolescents and Youth (TODAY) trial demonstrated that glycemic failure rates were significantly lower in youth randomized to metformin plus rosiglitazone treatment than in youth randomized to metformin alone or metformin plus intensive lifestyle intervention. At the end of the study, rosiglitazone was permanently discontinued, and routine diabetes care resumed. Herein, we report postintervention glycemic failure rates in TODAY participants over an additional 36 months of follow-up for the three original treatment arms and describe insulin sensitivity and β-cell function outcomes. RESEARCH DESIGN AND METHODS: A total of 699 participants were randomized during TODAY, of whom 572 enrolled in the TODAY2 observational follow-up. Glycemic failure was defined as HbA1c ≥8% over a 6-month period, inability to wean from temporary insulin therapy within 3 months after acute metabolic decompensation during TODAY, or sustained HbA1c ≥8% over two consecutive visits during TODAY2. Oral glucose tolerance tests were conducted, and insulin sensitivity, insulinogenic index, and oral disposition index were calculated. RESULTS: During the 36 months of TODAY2, glycemic failure rates did not differ among participants by original treatment group assignment. Insulin sensitivity and β-cell function deteriorated rapidly during the 36 months of TODAY2 routine diabetes care but did not differ by treatment group assignment. CONCLUSIONS: The added benefit of preventing glycemic failure by using rosiglitazone as a second agent in youth-onset type 2 diabetes did not persist after its discontinuation. More work is needed to address this rapid progression to avoid long-term diabetes complications.
引用
- Postintervention Effects of Varying Treatment Arms on Glycemic Failure and β-Cell Function in the TODAY Trial. Diabetes Care. 2020. PMID: 33290248. doi:10.2337/dc20-0622
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。